Human upcyte hepatocytes: Characterization of the hepatic phenotype and evaluation for acute and long-term hepatotoxicity routine testing

Toxicological Sciences

Volumn 152, Issue 1, 2016, Pages 214-229

  Tolosa, Laia ^a   Gómez Lechón, M José ^a,b   López, Silvia ^b   Guzmán, Carla ^a   Castell, José V ^a,b,c   Donato, M Teresa ^a,b,c   Jover, Ramiro ^a,b,c  

^a INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Acute and long term toxicity; Conjugating enzymes; Cytochrome P450; Hepatocytes; HepG2 cells; Steatosis; Transcriptomics; Upcyte hepatocytes

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; 1 NAPHTHYL ISOTHIOCYANATE; ALBUMIN; AMFEBUTAMONE; AMIODARONE; BIOLOGICAL MARKER; BUFURALOL; CHLORIDE; CHLORPROMAZINE; CHLORZOXAZONE; COUMARIN; CUMENE HYDROPEROXIDE; CYCLOSPORIN A; CYTOCHROME C; CYTOCHROME P450; DEXAMETHASONE; DICLOFENAC; DOXYCYCLINE; DRUG METABOLIZING ENZYME; ESTRADIOL; GLIBENCLAMIDE; GLYCOGEN; KETOTIFEN; LIPID; MAPROTILINE; MEPHENYTOIN; MIDAZOLAM; TRANSCRIPTION FACTOR; UNINDEXED DRUG; UREA; ISOENZYME; TRANSCRIPTOME;

ACUTE TOXICITY; ADULT; ARTICLE; CHILD; CHRONIC TOXICITY; CONTROLLED STUDY; CYTOTOXICITY TEST; ENZYME INDUCTION; FATTY LIVER; GENE EXPRESSION PROFILING; GLYCOGEN SYNTHESIS; HEPG2 CELL LINE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER FUNCTION; LIVER METABOLISM; LIVER TOXICITY; METABOLOMICS; MIDDLE AGED; MODEL; NEWBORN; OXIDATIVE STRESS; PHENOTYPE; REGULATORY MECHANISM; RISK ASSESSMENT; SCHOOL CHILD; TOXIC HEPATITIS; TRANSCRIPTOMICS; UPCYTE HEPATOCYTE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HEP-G2 CELL LINE; LIVER; METABOLISM; PATHOLOGY; PRIMARY CELL CULTURE; PROCEDURES; TIME FACTOR; TOXICITY TESTING;

CHEMICAL AND DRUG INDUCED LIVER INJURY; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFANT, NEWBORN; ISOENZYMES; LIVER; MIDDLE AGED; OXIDATIVE STRESS; PHENOTYPE; PRIMARY CELL CULTURE; RISK ASSESSMENT; TIME FACTORS; TOXICITY TESTS; TRANSCRIPTOME; TRANSFECTION;

EID: 84991396724     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfw078     Document Type: Article

References (58)

1. Abraham, V. C., Towne, D. L., Waring, J. F., Warrior, U., and Burns, D. J. (2008). Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. J. Biomol. Screen 13, 527-537.
2. Antherieu, S., Chesne, C., Li, R., Guguen-Guillouzo, C., and Guillouzo, A. (2012). Optimization of the HepaRG cell model for drug metabolism and toxicity studies. Toxicol. In Vitro 26, 1278-1285.
3. Benet, M., Lahoz, A., Guzman, C., Castell, J. V., and Jover, R. (2010). CCAAT/enhancer-binding protein alpha (C/EBPalpha) and hepatocyte nuclear factor 4alpha (HNF4alpha) synergistically cooperate with constitutive androstane receptor to transactivate the human cytochrome P450 2B6 (CYP2B6) gene: application to the development of a metabolically competent human hepatic cell model. J. Biol. Chem. 285, 28457-28471.
4. Benet, M., Moya, M., Donato, M. T., Lahoz, A., Hervas, D., Guzman, C., Gomez-Lechon, M. J., Castell, J. V., and Jover, R. (2014). A simple transcriptomic signature able to predict drug-induced hepatic steatosis. Arch. Toxicol. 88, 967-982.
5. Bjornsson, E. S., Bergmann, O. M., Bjornsson, H. K., Kvaran, R. B., and Olafsson, S. (2013). Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144, 1419-1425.
6. Bonora-Centelles, A., Donato, M. T., Lahoz, A., Pareja, E., Mir, J., Castell, J.V., andGomez-Lechon, M. J. (2010). Functional characterization of hepatocytes for cell transplantation: customized cell preparation for each receptor. Cell Transplant. 19, 21-28.
7. Burkard, A., Dahn, C., Heinz, S., Zutavern, A., Sonntag-Buck, V., Maltman, D., Przyborski, S., Hewitt, N. J., and Braspenning, J. (2012). Generation of proliferating human hepatocytes using Upcyte(R) technology: characterisation and applications in induction and cytotoxicity assays. Xenobiotica 42, 939-956.
8. Carretero, A., Leon, Z., Garcia-Canaveras, J. C., Zaragoza, A., Gomez-Lechon, M. J., Donato, M. T., and Lahoz, A. (2014). In vitro/in vivo screening of oxidative homeostasis and damage to DNA, protein, and lipids using UPLC/MS-MS. Anal. Bioanal. Chem. 406, 5465-5476.
9. Donato, M. T., Jover, R., and Gomez-Lechon, M. J. (2013). Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering. Curr. Drug Metab. 14, 946-968.
10. Donato, M. T., Lahoz, A., Jimenez, N., Perez, G., Serralta, A., Mir, J., Castell, J. V., and Gomez-Lechon, M. J. (2006). Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab. Dispos. 34, 1556-1562.
11. Donato, M. T., Lahoz, A., Montero, S., Bonora, A., Pareja, E., Mir, J., Castell, J. V., and Gomez-Lechon, M. J. (2008). Functional assessment of the quality of human hepatocyte preparations for cell transplantation. Cell Transplant. 17, 1211-1219.
12. Donato, M. T., Martinez-Romero, A., Jimenez, N., Negro, A., Herrera, G., Castell, J. V., O'Connor, J. E., and Gomez-Lechon, M. J. (2009). Cytometric analysis for drug-induced steatosis in HepG2 cells. Chem Biol. Interact. 181, 417-423.
13. Donato, M. T., Montero, S., Castell, J. V., Gomez-Lechon, M. J., and Lahoz, A. (2010). Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studies. Anal. Bioanal. Chem. 396, 2251-2263.
14. Donato, M. T., Tolosa, L., and Gomez-Lechon, M. J. (2015). Culture and functional characterization of human hepatoma HepG2 cells. Methods Mol. Biol. 1250, 77-93.
15. Donato, M. T., Tolosa, L., Jimenez, N., Castell, J. V., and Gomez-Lechon, M. J. (2012). High-content imaging technology for the evaluation of drug-induced steatosis using a multiparametric cell-based assay. J. Biomol. Screen. 17, 394-400.
16. Falcon, A., Doege, H., Fluitt, A., Tsang, B., Watson, N., Kay, M. A., and Stahl, A. (2010). FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase. Am. J. Physiol. Endocrinol. Metab. 299, E384-E393.
17. Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Bottger, J., et al. (2013). Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch. Toxicol. 87, 1315-1530.
18. Goldstein, J. L., DeBose-Boyd, R. A., and Brown, M. S. (2006). Protein sensors for membrane sterols. Cell 124, 35-46.
19. Gomez-Lechon, M. J., Castell, J. V., and Donato, M. T. (2008). An update on metabolism studies using human hepatocytes in primary culture. Exp. Opin. Drug Metab. Toxicol. 4, 837-854.
20. Gomez-Lechon, M. J., Donato, M. T., Castell, J. V., and Jover, R. (2004). Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr. Drug Metab. 5, 443-462.
21. Gomez-Lechon, M. J., Lahoz, A., Castell, J. V., and Donato, M. T. (2012). Evaluation of cytochrome P450 activities in human hepatocytes in vitro. Methods Mol. Biol. 806, 87-97.
22. Gomez-Lechon, M. J., Tolosa, L., Castell, J. V., and Donato, M. T. (2010). Mechanism-based selection of compounds for the development of innovative in vitro approaches to hepatotoxicity studies in the LIINTOP project. Toxicol. In Vitro 24, 1879-1889.
23. Gomez-Lechon, M. J., Tolosa, L., Conde, I., and Donato, M. T. (2014). Competency of different cell models to predict human hepatotoxic drugs. Exp. Opin. Drug Metab. Toxicol. 10, 1553-1568.
24. Gunness, P., Mueller, D., Shevchenko, V., Heinzle, E., Ingelman-Sundberg, M., and Noor, F. (2013). 3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies. Toxicol. Sci. 133, 67-78.
25. Hammond, K. D., and Balinsky, D. (1978). Activities of key gluconeogenic enzymes and glycogen synthase in rat and human livers, hepatomas, and hepatoma cell cultures. Cancer Res. 38, 1317-1322.
26. He, K., Cai, L., Shi, Q., Liu, H., and Woolf, T. F. (2015). Inhibition of MDR3 activity in human hepatocytes by drugs associated with liver injury. Chem. Res. Toxicol. 28, 1987-1990.
27. Hewitt, N. J., Lechon, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007). Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev. 39, 159-234.
28. Hines, R. N. (2013). Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int. J. Pharm. 452, 3-7.
29. James, S. J., Cutler, P., Melnyk, S., Jernigan, S., Janak, L., Gaylor, D. W., and Neubrander, J. A. (2004). Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am. J. Clin. Nutr. 80, 1611-1617.
30. Klein, M., Thomas, M., Hofmann, U., Seehofer, D., Damm, G., and Zanger, U. M. (2015). A systematic comparison of the impact of inflammatory signaling on absorption, distribution, metabolism, and excretion gene expression and activity in primary human hepatocytes and HepaRG cells. Drug Metab. Dispos. 43, 273-283.
31. Levy, G., Bomze, D., Heinz, S., Ramachandran, S. D., Noerenberg, A., Cohen, M., Shibolet, O., Sklan, E., Braspenning, J., and Nahmias, Y. (2015). Long-term culture and expansion of primary human hepatocytes. Nat. Biotechnol. 33, 1264-1271.
32. Lewis, D. F., Ioannides, C., and Parke, D. V. (1998). Cytochromes P450 and species differences in xenobiotic metabolism and activation of carcinogen. Environ. Health Perspect 106, 633-641.
33. Martinez-Jimenez, C. P., Gomez-Lechon, M. J., Castell, J. V., and Jover, R. (2006). Underexpressed coactivators PGC1alpha and SRC1 impair hepatocyte nuclear factor 4 alpha function and promote dedifferentiation in human hepatoma cells. J. Biol. Chem. 281, 29840-29849.
34. Morris, S. M., Jr., Kepka, D. M., Sweeney, W. E Jr., and Avner, E. D. (1989). Abundance of mRNAs encoding urea cycle enzymes in fetal and neonatal mouse liver. Arch. Biochem. Biophys. 269, 175-180.
35. Noda, Y., Lee, S. A., Choi, Y. Y., Park, D., Jang, J. Y., Kim, D. S., and Lee, S. H. (2012). Functional 3D human primary hepatocyte spheroids made by co-culturing hepatocytes from partial hepatectomy specimens and human adipose-derived stem cells. PLoS One 7, e50723.
36. Norenberg, A., Heinz, S., Scheller, K., Hewitt, N. J., Braspenning, J., and Ott, M. (2013). Optimization of upcyte(R) human hepatocytes for the in vitro micronucleus assay. Mutat. Res. 758, 69-79.
37. O'Brien, P. J., Chan, K., and Silber, P. M. (2004). Human and animal hepatocytes in vitro with extrapolation in vivo. Chem. Biol. Interact. 150, 97-114.
38. O'Brien, P. J., Irwin, W., Diaz, D., Howard-Cofield, E., Krejsa, C. M., Slaughter, M. R., Gao, B., Kaludercic, N., Angeline, A., Bernardi, P., et al. (2006). High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 80, 580-604.
39. Pascussi, J. M., Gerbal-Chaloin, S., Drocourt, L., Maurel, P., and Vilarem, M. J. (2003). The expression of CYP2B6, CYP2C9 and CYP3A4 genes: A tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta. 1619, 243-253.
40. Prieto, P., Baird, A. W., Blaauboer, B. J., Castell Ripoll, J. V., Corvi, R., Dekant, W., Dietl, P., Gennari, A., Gribaldo, L., Griffin, J. L., et al. (2006). The assessment of repeated dose toxicity in vitro: a proposed approach. The report and recommendations of ECVAM workshop 56. Altern. Lab. Anim. 34, 315-341.
41. Ramachandran, S. D., Vivares, A., Klieber, S., Hewitt, N. J., Muenst, B., Heinz, S., Walles, H., and Braspenning, J. (2015). Applicability of second-generation upcyte(R) human hepatocytes for use in CYP inhibition and induction studies. Pharmacol. Res. Perspect. 3, e00161.
42. Reuben, A., Koch, D. G., and Lee, W. M. (2010). Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 52, 2065-2076.
43. Rodriguez-Antona, C., Bort, R., Jover, R., Tindberg, N., Ingelman-Sundberg, M., Gomez-Lechon, M. J., and Castell, J. V. (2003). Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma. Mol. Pharmacol. 63, 1180-1189.
44. Saeed, A. I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., Currier, T., Thiagarajan, M., et al. (2003). TM4: A free, open-source system for microarray data management and analysis. Biotechniques 34, 374-378.
45. Schaefer, M., Schanzle, G., Bischoff, D., and Sussmuth, R. D. (2016). Upcyte human hepatocytes: a potent in vitro tool for the prediction of hepatic clearance of metabolically stable compounds. Drug Metab. Dispos. 44, 435-444.
46. Schoonen, W. G., Stevenson, J. C., Westerink, W. M., and Horbach, G. J. (2012). Cytotoxic effects of 109 reference compounds on rat H4IIE and human HepG2 hepatocytes. III: Mechanistic assays on oxygen consumption with MitoXpress and NAD(P)H production with Alamar Blue. Toxicol. In Vitro 26, 511-525.
47. Sharov, A. A., Dudekula, D. B., and Ko, M. S. (2005). A web-based tool for principal component and significance analysis of microarray data. Bioinformatics 21, 2548-2549.
48. Sison-Young, R. L., Mitsa, D., Jenkins, R. E., Mottram, D., Alexandre, E., Richert, L., Aerts, H., Weaver, R. J., Jones, R. P., Johann, E., et al. (2015). Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication. Toxicol. Sci. 147, 412-424.
49. Thompson, R. A., Isin, E. M., Li, Y., Weidolf, L., Page, K., Wilson, I., Swallow, S., Middleton, B., Stahl, S., Foster, A. J., et al. (2012). In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem. Res. Toxicol. 25, 1616-1632.
50. Tolosa, L., Carmona, A., Castell, J. V., Gomez-Lechon, M. J., and Donato, M. T. (2015a). High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins. Arch. Toxicol. 89, 1847-1860.
51. Tolosa, L., Gomez-Lechon, M. J., and Donato, M. T. (2015b). Highcontent screening technology for studying drug-induced hepatotoxicity in cell models. Arch. Toxicol. 89, 1007-1022.
52. Tolosa, L., Pareja-Ibars, E., Donato, M. T., Cortes, M., Lopez, S., Jimenez, N., Mir, J., Castell, J. V., and Gomez-Lechon, M. J. (2014). Neonatal livers: a source for the isolation of good-performing hepatocytes for cell transplantation. Cell Transplant. 23, 1229-1242.
53. Tolosa, L., Pinto, S., Donato, M. T., Lahoz, A., Castell, J. V., O'Connor, J. E., and Gomez-Lechon, M. J. (2012). Development of amultiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. Toxicol. Sci. 127, 187-198.
54. Ulvestad, M., Nordell, P., Asplund, A., Rehnstrom, M., Jacobsson, S., Holmgren, G., Davidson, L., Brolen, G., Edsbagge, J., Bjorquist, P., et al. (2013). Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. Biochem. Pharmacol. 86, 691-702.
55. Vanhaecke, T., Pauwels, M., Vinken, M., Ceelen, L., and Rogiers, V. (2011). Towards an integrated in vitro strategy for repeated dose toxicity testing. Arch. Toxicol. 85, 365-366.
56. Vila-Brau, A., De Sousa-Coelho, A. L., Mayordomo, C., Haro, D., and Marrero, P. F. (2011). Human HMGCS2 regulates mitochondrial fatty acid oxidation and FGF21 expression in HepG2 cell line. J. Biol. Chem. 286, 20423-20430.
57. Wilkening, S., Stahl, F., and Bader, A. (2003). Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab. Dispos. 31, 1035-1042.
58. Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., and de Graaf, D. (2008). Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105, 97-105.